We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Annovis Bio Inc | NYSE:ANVS | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.1704 | 3.29% | 5.3504 | 5.76 | 5.21 | 5.30 | 397,720 | 22:00:22 |
From May 2022 to May 2024
By Chris Wack
Annovis Bio Inc. shares were up 6% to $14.18 early Thursday after the drug-platform company said the U.S. Food and Drug Administration authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease.
Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the company requested approval to further pursue the development of buntanetap in AD.
The FDA approved the company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.
Annovis stock is up 40% in the last month.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 06, 2022 10:19 ET (14:19 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Annovis Bio Chart |
1 Month Annovis Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
